EP2224924A4 - Zusammensetzungen und verfahren zur behandlung von zystischer fibrose - Google Patents

Zusammensetzungen und verfahren zur behandlung von zystischer fibrose

Info

Publication number
EP2224924A4
EP2224924A4 EP08841991A EP08841991A EP2224924A4 EP 2224924 A4 EP2224924 A4 EP 2224924A4 EP 08841991 A EP08841991 A EP 08841991A EP 08841991 A EP08841991 A EP 08841991A EP 2224924 A4 EP2224924 A4 EP 2224924A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
cystic fibrosis
cystic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08841991A
Other languages
English (en)
French (fr)
Other versions
EP2224924A1 (de
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/en
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/en
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Priority claimed from PCT/US2008/081113 external-priority patent/WO2009055671A1/en
Publication of EP2224924A1 publication Critical patent/EP2224924A1/de
Publication of EP2224924A4 publication Critical patent/EP2224924A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
EP08841991A 2007-10-25 2008-10-24 Zusammensetzungen und verfahren zur behandlung von zystischer fibrose Withdrawn EP2224924A4 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US98271907P 2007-10-25 2007-10-25
US98272007P 2007-10-25 2007-10-25
PCT/US2007/082581 WO2008115290A2 (en) 2006-10-25 2007-10-25 Methods of wound care and treatment
PCT/US2007/082580 WO2008052145A2 (en) 2006-10-25 2007-10-25 Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
PCT/US2007/082578 WO2008052143A2 (en) 2006-10-25 2007-10-25 Mixing device and output fluids of same
US4833208P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
US4834008P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
PCT/US2008/081113 WO2009055671A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating cystic fibrosis

Publications (2)

Publication Number Publication Date
EP2224924A1 EP2224924A1 (de) 2010-09-08
EP2224924A4 true EP2224924A4 (de) 2011-01-12

Family

ID=42261767

Family Applications (3)

Application Number Title Priority Date Filing Date
EP08842968A Withdrawn EP2215260A4 (de) 2007-10-25 2008-10-23 Zusammensetzungen und verfahren zur modulation zellmembranvermittelter intrazellulärer signalweiterleitung
EP08841991A Withdrawn EP2224924A4 (de) 2007-10-25 2008-10-24 Zusammensetzungen und verfahren zur behandlung von zystischer fibrose
EP08841701.9A Active EP2214707B1 (de) 2007-10-25 2008-10-24 Zusammensetzungen und verfahren zur behandlung von entzündungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08842968A Withdrawn EP2215260A4 (de) 2007-10-25 2008-10-23 Zusammensetzungen und verfahren zur modulation zellmembranvermittelter intrazellulärer signalweiterleitung

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08841701.9A Active EP2214707B1 (de) 2007-10-25 2008-10-24 Zusammensetzungen und verfahren zur behandlung von entzündungen

Country Status (8)

Country Link
EP (3) EP2215260A4 (de)
JP (6) JP5613565B2 (de)
CN (5) CN101910412B (de)
AU (3) AU2008316794B2 (de)
CA (3) CA2703672A1 (de)
IL (3) IL205317A (de)
MX (3) MX2010004563A (de)
WO (1) WO2009055614A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
CA2667791A1 (en) 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP3170401B1 (de) 2006-10-25 2019-06-05 Revalesio Corporation Ionische wässrige flüssigkeitszusammensetzung enthaltend sauerstoffmikroblasen
MX2010004563A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular.
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
WO2009055620A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
JP5539965B2 (ja) * 2008-04-28 2014-07-02 レバレジオ コーポレイション 多発性硬化症を治療するための組成物および方法
CN103919804A (zh) 2008-05-01 2014-07-16 利发利希奥公司 治疗消化功能紊乱的组合物和方法
MX2011004233A (es) * 2008-10-22 2011-06-24 Revalesio Corp Composiciones y metodos para tratar las condiciones producidas por la matriz-metaloproteinasa 9 (mmp9).
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
BRPI1013992A2 (pt) * 2009-04-27 2016-08-16 Revalesio Corp composições e métodos para o tratamento de resistência à insulina e diabetes melito
KR20130114581A (ko) 2010-05-07 2013-10-18 레발레시오 코퍼레이션 생리적 수행능력 및 회복 시간의 향상을 위한 조성물 및 방법
US9044479B2 (en) 2010-06-16 2015-06-02 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
BR112013003110A2 (pt) 2010-08-12 2016-06-28 Revalesio Corp composições e métodos para tratamento de taupatia
CN103347493A (zh) * 2010-08-13 2013-10-09 利发利希奥公司 用于治疗心血管疾病的组合物和方法
MX2013011888A (es) * 2011-04-13 2014-02-27 Revalesio Corp Composiciones y metodos para inhibir y/o modular las celulas-t efectoras involucradas en la enfermedad neurodegenerativa inflamatoria.
JP6368459B2 (ja) * 2012-06-14 2018-08-01 松本　高明 点眼液の製造方法
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
ES2745041T3 (es) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
CN110769840A (zh) * 2017-05-23 2020-02-07 碧澳维特澳大利亚股份有限公司 源自节螺藻属的提取物及其用途
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
CN112305153B (zh) * 2020-10-16 2022-09-23 中石化石油工程技术服务有限公司 一种膨润土含量的自动分析检测仪及其检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040129112A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Metal-containing materials
WO2005113026A2 (en) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518483D0 (en) * 1995-09-09 1995-11-08 Thompson Royce Ltd Lighting control systems
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US20020102604A1 (en) * 1999-12-08 2002-08-01 Milne Edwards Jean-Baptiste Dumas Full-length human cDNAs encoding potentially secreted proteins
EP1100811B1 (de) * 1998-07-28 2007-07-04 The Regents Of The University Of California Für einen g-protein gekoppelten rezeptor, der an der empfindungstransduktion beteiligt ist, kodierende nukleinsäuren
BR0015223A (pt) * 1999-10-26 2002-06-18 Bio Hydration Res Lab Inc Lìquidos em micro-feixes e métodos para fazê-los e usá-los
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
AU2001292867A1 (en) * 2000-09-20 2002-04-02 The Cleveland Clinic Foundation Ligands for g protein coupled receptors and methods of using them
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US6649145B2 (en) * 2001-02-01 2003-11-18 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
DE10227818A1 (de) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gasanreicherungsmodule
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
RU2372339C2 (ru) * 2003-11-10 2009-11-10 Мерк Энд Ко., Инк. Замещенные триазолы в качестве блокаторов натриевых каналов
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
AU2005329764B2 (en) * 2005-03-28 2010-08-12 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (II) antitumour agents
MX359219B (es) * 2005-05-18 2018-09-19 Raptor Pharmaceuticals Inc Fluoroquinolonas aerosolizadas y sus usos.
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2667791A1 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
WO2008115290A2 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Methods of wound care and treatment
WO2009055620A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
MX2010004563A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040129112A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Metal-containing materials
WO2005113026A2 (en) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILL S ET AL: "Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - A review", JOURNAL OF BIOMEDICAL NANOTECHNOLOGY 200706 US LNKD- DOI:10.1166/JBN.2007.015, vol. 3, no. 2, June 2007 (2007-06-01), pages 107 - 119, XP009141494, ISSN: 1550-7033 *
See also references of WO2009055671A1 *

Also Published As

Publication number Publication date
IL205317A (en) 2016-03-31
MX2010004554A (es) 2010-07-28
CA2703754A1 (en) 2009-04-30
EP2214707A1 (de) 2010-08-11
CN101909648A (zh) 2010-12-08
EP2215260A4 (de) 2011-04-20
WO2009055614A1 (en) 2009-04-30
AU2008316623A1 (en) 2009-04-30
CA2703672A1 (en) 2009-04-30
CA2703754C (en) 2019-04-09
JP2014205693A (ja) 2014-10-30
JP5869763B2 (ja) 2016-02-24
EP2214707B1 (de) 2017-07-12
IL205317A0 (en) 2010-12-30
JP2011500844A (ja) 2011-01-06
AU2008316794B2 (en) 2015-04-23
AU2008316663B2 (en) 2014-12-18
CN101909623A (zh) 2010-12-08
MX2010004564A (es) 2010-07-28
CN103933567A (zh) 2014-07-23
EP2215260A1 (de) 2010-08-11
IL205318A0 (en) 2010-12-30
CN104771758A (zh) 2015-07-15
CN101909623B (zh) 2015-04-01
AU2008316663A1 (en) 2009-04-30
JP2014193915A (ja) 2014-10-09
JP2011500837A (ja) 2011-01-06
JP2014169328A (ja) 2014-09-18
IL205319A (en) 2016-06-30
AU2008316623B2 (en) 2015-01-22
CN101910412A (zh) 2010-12-08
JP2011500847A (ja) 2011-01-06
MX2010004563A (es) 2010-07-28
JP5613565B2 (ja) 2014-10-22
IL205318A (en) 2017-01-31
EP2214707A4 (de) 2011-04-20
AU2008316794A1 (en) 2009-04-30
CN101910412B (zh) 2013-08-21
CN101909648B (zh) 2014-04-16
JP5911197B2 (ja) 2016-04-27
IL205319A0 (en) 2010-12-30
EP2224924A1 (de) 2010-09-08
CA2703739A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
EP2224924A4 (de) Zusammensetzungen und verfahren zur behandlung von zystischer fibrose
EP2376410A4 (de) Reinigungsmittel und verfahren
EP2209371A4 (de) Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
EP2271301A4 (de) Verfahren und zusammensetzungen zur abgabe von mitteln
EP2340027A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP2376656A4 (de) Verfahren und bestimmung der wirksamkeit einer glucocorticoidbehandlung von eosinophiler ösophagitis
EP2262474A4 (de) Verfahren und zusammensetzungen zur wundheilung
EP2207669A4 (de) Bakteriostatische oder bakteriozide zusammensetzungen und verfahren
EP2120580A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
HUE042901T2 (hu) Készítmények és eljárások IgE által közvetített rendellenességek kezelésére
EP2352517A4 (de) Verfahren und zusammensetzungen zur behandlung von komplementassoziierten erkrankungen
EP2092445A4 (de) Verschachtelung von suchergebnissen
EP2056675A4 (de) Methode zur behandlung oraler mukositis
EP2365978A4 (de) Lecithin- und weichmacherzusammensetzungen und verfahren
EP2286217A4 (de) Verfahren und zusammensetzung zur ladung von einzelmolekülen
EP2207424A4 (de) Zusammensetzungen und verfahren zur behandlung von purpura
EP2320937A4 (de) Zusammensetzungen und verfahren zur behandlung von okularem oxidativem stress und retinitis pigmentosa
EP2271329A4 (de) Verfahren, zusammensetzungen und sets zur behandlung von schmerzen und pruritis
EP2344447A4 (de) Gaba-konjugate und verfahren zu ihrer verwendung
EP2300011A4 (de) Therapeutische verfahren und verbindungen
EP2294192A4 (de) Zusammensetzungen und verfahren zur behandlung von und impfung gegen dengue-virus (dv)
EP2068865A4 (de) Verfahren und zusammensetzungen für therapiebehandlung
EP2349320A4 (de) Zusammensetzungen und verfahren zur behandlung von nierenerkrankungen
EP2419136A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP2211856A4 (de) Zusammensetzungen und verfahren zur behandlung lysosomaler störungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20101213

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140822

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160927